Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.

Abstract:

:In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P < 0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/ml, P = 0.045) and a decrease of sHER2 levels during NT (P = 0.02), which was also significant in multivariate analysis (OR = 3.29, 95% CI 1.001-10.89, P = 0.049). In HER2-negative patients, we observed no association between sHER2 levels and pCR (P > 0.05). Monitoring sHER2 levels in the presence of anti-HER2 treatment might be an adjunct to the clinical evaluation during NT.

authors

Witzel I,Loibl S,von Minckwitz G,Mundhenke C,Huober J,Hanusch C,Henschen S,Hauschild M,Lantzsch T,Tesch H,Latos K,Just M,Hilfrich J,Barinoff J,Eulenburg CZ,Roller M,Untch M,Müller V

doi

10.1007/s10549-010-1030-9

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

437-45

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

123

pub_type

杂志文章,多中心研究,随机对照试验
  • Factors predicting in-breast tumor recurrence after breast-conserving surgery.

    abstract:PURPOSE:The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival. METHODS:A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0187-y

    authors: Mechera R,Viehl CT,Oertli D

    更新日期:2009-07-01 00:00:00

  • MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

    abstract::The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary lymphatic spread in breast cancer patients. Biopsies from breast cancer (...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9400-z

    authors: Bathen TF,Jensen LR,Sitter B,Fjösne HE,Halgunset J,Axelson DE,Gribbestad IS,Lundgren S

    更新日期:2007-08-01 00:00:00

  • Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis.

    abstract:PURPOSE:Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or ad...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4345-y

    authors: Diwanji TP,Molitoris JK,Chhabra AM,Snider JW,Bentzen SM,Tkaczuk KH,Rosenblatt PY,Kesmodel SB,Bellavance EC,Cohen RJ,Cheston SB,Nichols EM,Feigenberg SJ

    更新日期:2017-09-01 00:00:00

  • Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

    abstract::Prognosis of early beast cancer is heterogeneous. Today, no histoclinical or biological factor predictive for clinical outcome after adjuvant anthracycline-based chemotherapy (CT) has been validated and introduced in routine use. Using DNA microarrays, we searched for a gene expression signature associated with metast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1003-z

    authors: Bertucci F,Borie N,Roche H,Bachelot T,Le Doussal JM,Macgrogan G,Debono S,Martinec A,Treilleux I,Finetti P,Esterni B,Extra JM,Geneve J,Hermitte F,Chabannon C,Jacquemier J,Martin AL,Longy M,Maraninchi D,Fert V,Birnb

    更新日期:2011-06-01 00:00:00

  • Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.

    abstract:PURPOSE:Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcome...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05352-3

    authors: Aleixo GFP,Williams GR,Nyrop KA,Muss HB,Shachar SS

    更新日期:2019-10-01 00:00:00

  • Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.

    abstract::Erratum to: Breast Cancer Res Treat (2012),134:549–560,DOI 10.1007/s10549-012-2080-y. In the original publication of the article, Fig. 5c was published incorrectly. The authors apologize for this error and the correct Fig. 5c is given below. ...

    journal_title:Breast cancer research and treatment

    pub_type: 已发布勘误

    doi:10.1007/s10549-016-3703-5

    authors: Tang J,Deng R,Luo RZ,Shen GP,Cai MY,Du ZM,Jiang S,Yang MT,Fu JH,Zhu XF

    更新日期:2016-04-01 00:00:00

  • Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients.

    abstract:PURPOSE:In left-sided breast cancer radiotherapy, tangential intensity modulated radiotherapy combined with breath-hold enables a dose reduction to the heart and left anterior descending (LAD) coronary artery. Aim of this study was to investigate the added value of intensity modulated proton therapy (IMPT) with regard ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3149-6

    authors: Mast ME,Vredeveld EJ,Credoe HM,van Egmond J,Heijenbrok MW,Hug EB,Kalk P,van Kempen-Harteveld LM,Korevaar EW,van der Laan HP,Langendijk JA,Rozema HJ,Petoukhova AL,Schippers JM,Struikmans H,Maduro JH

    更新日期:2014-11-01 00:00:00

  • Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population.

    abstract::Genome-Wide Association Studies have identified several loci associated with breast cancer (BC) in populations of different ethnic origins. One of the strongest associations was found in the FGFR2 gene, and MAP3K1 has been proposed as a low-penetrance BC risk factor. In this study, we evaluated the associations among ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2359-z

    authors: Jara L,Gonzalez-Hormazabal P,Cerceño K,Di Capua GA,Reyes JM,Blanco R,Bravo T,Peralta O,Gomez F,Waugh E,Margarit S,Ibañez G,Romero C,Pakomio J,Roizen G

    更新日期:2013-01-01 00:00:00

  • Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas.

    abstract::The expression of amphiregulin (AR), heregulin (HRG), and cripto-1 (CR-1) mRNA transcripts was assessed in 60 human primary breast carcinoma. AR and HRG transcripts were expressed respectively in 58% and 25% of the carcinomas as measured by Northern blot analysis. CR-1 mRNA was found in 77% of the carcinomas using Rev...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665981

    authors: Normanno N,Kim N,Wen D,Smith K,Harris AL,Plowman G,Colletta G,Ciardiello F,Salomon DS

    更新日期:1995-09-01 00:00:00

  • Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers.

    abstract::Co-transfection studies indicate that HER2 (erbB-2) overexpression results in the phosphorylation and enhanced transcriptional activity of the androgen receptor (AR). This amplification of AR action is further enhanced by the expression of ARA70, a putative co-activator with a predilection for the AR. Because androgen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1017938608460

    authors: Kollara A,Kahn HJ,Marks A,Brown TJ

    更新日期:2001-06-01 00:00:00

  • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.

    abstract:INTRODUCTION:Breast cancer (BC) is the leading cause of cancer death in Caribbean women. Across the Caribbean islands, the prevalence of hereditary breast cancer among unselected breast cancer patients ranges from 5 to 25%. Moreover, the prevalence of BC among younger women and the high mortality in the Caribbean regio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5045-y

    authors: Donenberg T,George S,Ali J,Bravo G,Hernandez K,Sookar N,Ashing KT,Narod SA,Akbari MR,Hurley J

    更新日期:2019-04-01 00:00:00

  • Sensory changes after treatment of operable breast cancer.

    abstract::A study has been conducted to compare the nature and severity of post-operative sensory changes (sensory loss, paraesthesiae, and pain) among patients with breast cancer treated by either modified radical mastectomy or a conservative procedure (tumourectomy, axillary clearance, iridium implant, and external radiothera...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805925

    authors: Karydas I,Fentiman IS,Habib F,Hayward JL

    更新日期:1986-01-01 00:00:00

  • A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (

    abstract:PURPOSE:Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer trastuzumab resistance. A combination of SAHA and trastuzumab may be a promising strategy to improve the efficacy of trastuzumab against breast cancer. In this Pha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4310-9

    authors: Goldstein LJ,Zhao F,Wang M,Swaby RF,Sparano JA,Meropol NJ,Bhalla KN,Pellegrino CM,Katherine Alpaugh R,Falkson CI,Klein P,Sledge GW

    更新日期:2017-09-01 00:00:00

  • Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    abstract::One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2149-7

    authors: Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

    更新日期:2012-08-01 00:00:00

  • Thrombocytosis as a prognostic factor in inflammatory breast cancer.

    abstract:PURPOSE:Platelets are essential components of hemostasis and also play an important role in the tumor microenvironment. The purposes of our research were to examine the role of thrombocytosis in inflammatory breast cancer (IBC) and to know which cytokine drives thrombocytosis. METHODS:We reviewed the medical records o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4463-6

    authors: Harano K,Kogawa T,Wu J,Yuan Y,Cohen EN,Lim B,Reuben JM,Ueno NT

    更新日期:2017-12-01 00:00:00

  • Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone

    abstract:BACKGROUND:This study evaluated the cost-effectiveness of anastrozole versus generic tamoxifen for primary adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC), from a US healthcare perspective. METHODS:A probabilistic Markov model was developed using the 5-year com...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9483-6

    authors: Locker GY,Mansel R,Cella D,Dobrez D,Sorensen S,Gandhi SK,ATAC Trialists' Group.

    更新日期:2007-12-01 00:00:00

  • Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.

    abstract:PURPOSE:To estimate the performance of diffusion-weighted imaging (DWI) for breast cancer detection. METHODS:Consecutive breast magnetic resonance imaging examinations performed from January to September 2016 were retrospectively evaluated. Examinations performed before/after neoadjuvant therapy, lacking DWI sequences...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05519-y

    authors: Rotili A,Trimboli RM,Penco S,Pesapane F,Tantrige P,Cassano E,Sardanelli F

    更新日期:2020-02-01 00:00:00

  • William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms.

    abstract::Over the past two decades, the simple model for control of breast cancer growth involving one or two factors acting directly or indirectly via endocrine pathways has turned into a complex model implicating numerous interacting factors and the diverse cell populations constituting breast tumors. Current approaches to b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00683193

    authors: Freiss G,Prébois C,Vignon F

    更新日期:1993-01-01 00:00:00

  • Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.

    abstract:PURPOSE:Triple-negative breast cancers (TNBC) are aggressive tumours that exhibit abundant lymphoid infiltrates which modulate tumour behaviour. Recent findings suggest that TNBC with higher densities of plasma cells are associated with a favourable prognosis, and tertiary lymphoid structures (TLS) have prognostic sign...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05548-y

    authors: Seow DYB,Yeong JPS,Lim JX,Chia N,Lim JCT,Ong CCH,Tan PH,Iqbal J

    更新日期:2020-04-01 00:00:00

  • Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.

    abstract::In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-010-0843-x

    authors: Ma X,Chen C,Xiong H,Li Y

    更新日期:2010-11-01 00:00:00

  • Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls.

    abstract::Epidemiological studies have evaluated the association between catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. System...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-009-0650-4

    authors: Mao C,Wang XW,Qiu LX,Liao RY,Ding H,Chen Q

    更新日期:2010-06-01 00:00:00

  • Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

    abstract::Goserelin ('Zoladex'), a luteinizing hormone-releasing hormone (LHRH) agonist induces reversible ovarian ablation in premenopausal women. It is the most extensively studied LHRH agonist for the treatment of breast cancer and data from a large clinical trial program show that, alone or in combination with tamoxifen, go...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1020309715942

    authors: Jonat W

    更新日期:2002-10-01 00:00:00

  • The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.

    abstract:PURPOSE:Nuclear factor E2-related factor 2 (NRF2) is a transcription factor that plays a major role in the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated NRF2 overexpression with poor prognosis in a variety of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05494-4

    authors: Almeida M,Soares M,Ramalhinho AC,Moutinho JF,Breitenfeld L,Pereira L

    更新日期:2020-02-01 00:00:00

  • Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.

    abstract::We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005716214718

    authors: Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

    更新日期:1997-01-01 00:00:00

  • The clinical value of preoperative wire localization of breast lesions by magnetic resonance imaging--a multicenter study.

    abstract::To evaluate the clinical value of MRI guided preoperative wire localization of clinically and mammographically occult lesions of the breast. In a multicenter study, we evaluated 132 preoperative MRI guided localizations. Median lesion size evaluated by MRI prior to wire localization was 9mm. MRI guided localization wa...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1023/a:1019668210290

    authors: Lampe D,Hefler L,Alberich T,Sittek H,Perlet C,Prat X,Taourel P,Amaya B,Koelbl H,Heywang-Kobrunner SH

    更新日期:2002-09-01 00:00:00

  • Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.

    abstract::Trinucleotide repeat-containing 9 (TNRC9), a high mobility group chromatin-associated protein, has been implicated in breast cancer metastasis to the bone. Recently, several single nucleotide polymorphisms (SNPs) of TNRC9 were identified as novel breast cancer susceptibility loci by whole genome association studies, e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0809-z

    authors: Liang J,Chen P,Hu Z,Shen H,Wang F,Chen L,Li M,Tang J,Wang H,Shen H

    更新日期:2010-11-01 00:00:00

  • Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.

    abstract::The Women's Health Initiative (WHI) randomized trials found that use of combined estrogen and progestin menopausal hormone therapy (CHT) increases breast cancer risk, but use of unopposed estrogen hormone therapy (EHT) does not. However, several questions regarding the impact of hormone use on risk of different types ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2960-4

    authors: Li CI,Daling JR,Haugen KL,Tang MT,Porter PL,Malone KE

    更新日期:2014-06-01 00:00:00

  • Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ.

    abstract::Currently, there are no applied molecular markers to aid in predicting risk of carcinoma in situ (CIS) progression to invasive cancer, and therefore, all women diagnosed with CIS undergo surgery. Standard assessment of protein expression in fixed tissue by immunohistochemistry (IHC) is not quantitative and hence is no...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1227-y

    authors: Furstenau DK,Mitra N,Wan F,Lewis R,Feldman MD,Fraker DL,Guvakova MA

    更新日期:2011-09-01 00:00:00

  • Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy.

    abstract::Sentinel lymph node (SLN) biopsy is rapidly emerging as an alternative to axillary lymph node dissection (ALND) for many female breast cancer patients. In contrast, ALND remains the standard of care for male breast cancer patients with similar tumors. We evaluated the results of SLN biopsy in male breast cancer patien...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1021173902253

    authors: Albo D,Ames FC,Hunt KK,Ross MI,Singletary SE,Kuerer HM

    更新日期:2003-01-01 00:00:00

  • The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.

    abstract:PURPOSE:To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy. METHODS:A retrospective search of a prospectively maintained clinical database was performed to identify patients treated with neoadjuvant chemotherapy at the Roy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0081-7

    authors: Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

    更新日期:2009-07-01 00:00:00